JP2020510845A5 - - Google Patents

Download PDF

Info

Publication number
JP2020510845A5
JP2020510845A5 JP2019566047A JP2019566047A JP2020510845A5 JP 2020510845 A5 JP2020510845 A5 JP 2020510845A5 JP 2019566047 A JP2019566047 A JP 2019566047A JP 2019566047 A JP2019566047 A JP 2019566047A JP 2020510845 A5 JP2020510845 A5 JP 2020510845A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
seq
antagonist antibody
sema4d
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019566047A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020510845A (ja
JP7626416B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/018794 external-priority patent/WO2018156509A1/en
Publication of JP2020510845A publication Critical patent/JP2020510845A/ja
Publication of JP2020510845A5 publication Critical patent/JP2020510845A5/ja
Application granted granted Critical
Publication of JP7626416B2 publication Critical patent/JP7626416B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019566047A 2017-02-22 2018-02-20 神経変性疾患または神経炎症性疾患におけるグリア細胞活性化の早期検出方法 Active JP7626416B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762461945P 2017-02-22 2017-02-22
US62/461,945 2017-02-22
PCT/US2018/018794 WO2018156509A1 (en) 2017-02-22 2018-02-20 Early detection of glial cell activation in neurodegenerative or neuroinflammatory diseases

Publications (3)

Publication Number Publication Date
JP2020510845A JP2020510845A (ja) 2020-04-09
JP2020510845A5 true JP2020510845A5 (cg-RX-API-DMAC7.html) 2021-03-25
JP7626416B2 JP7626416B2 (ja) 2025-02-04

Family

ID=63253999

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019566047A Active JP7626416B2 (ja) 2017-02-22 2018-02-20 神経変性疾患または神経炎症性疾患におけるグリア細胞活性化の早期検出方法

Country Status (14)

Country Link
US (1) US20190383836A1 (cg-RX-API-DMAC7.html)
EP (1) EP3585435A4 (cg-RX-API-DMAC7.html)
JP (1) JP7626416B2 (cg-RX-API-DMAC7.html)
KR (1) KR102533921B1 (cg-RX-API-DMAC7.html)
CN (1) CN110325213A (cg-RX-API-DMAC7.html)
AU (1) AU2018225493B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019017367A2 (cg-RX-API-DMAC7.html)
CA (1) CA3050328A1 (cg-RX-API-DMAC7.html)
IL (1) IL267940B2 (cg-RX-API-DMAC7.html)
MX (1) MX2019009986A (cg-RX-API-DMAC7.html)
RU (1) RU2766341C2 (cg-RX-API-DMAC7.html)
SG (1) SG11201906670PA (cg-RX-API-DMAC7.html)
WO (1) WO2018156509A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201904431B (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2427212B1 (en) 2009-05-08 2017-08-23 Vaccinex, Inc. Anti-cd100 antibodies and methods for using the same
EA029023B1 (ru) 2011-10-11 2018-01-31 Вэксинекс, Инк. Применение молекул, связывающих семафорин-4d, для модуляции проницаемости гематоэнцефалического барьера
US9708601B2 (en) 2012-04-26 2017-07-18 Vaccinex, Inc. Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus
US10494440B2 (en) * 2012-05-11 2019-12-03 Vaccinex, Inc. Use of semaphorin-4D binding molecules to promote neurogenesis following stroke
US9243068B2 (en) 2013-06-25 2016-01-26 Vaccinex, Inc. Combination of SEMA-4D inhibitors and immunomodulators to inhibit tumors and metastases
NZ630892A (en) 2013-10-21 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treating neurodegenerative disorders
PT3445397T (pt) 2016-04-22 2023-01-13 Vaccinex Inc Exibição de proteína integral de membrana sobre viriões envelopados extracelulares de poxvírus
SG11201900595YA (en) 2016-08-02 2019-02-27 Vaccinex Inc Improved methods for producing polynucleotide libraries in vaccinia virus/eukaryotic cells
JP7246320B2 (ja) 2017-05-05 2023-03-27 バクシネックス インコーポレーティッド ヒト抗セマフォリン4d抗体
US11597765B2 (en) 2020-06-25 2023-03-07 Vaccinex, Inc. Use of semaphorin-4D binding molecules for the treatment of Rett syndrome
MX2024003883A (es) * 2021-09-27 2024-08-28 Vaccinex Inc Perfil predictivo de resultados para el uso de una molecula de union de antisemaforina-4d para el tratamiento de trastornos neurodegenerativos.
EP4692124A1 (en) * 2023-04-03 2026-02-11 Sialbio Co., Ltd. Pharmaceutical composition for preventing or treating sjogren's syndrome, containing recombinant anti-semaphorin 4d antibody as active ingredient

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0892047A3 (de) * 1997-07-09 2000-03-08 Hoechst Marion Roussel Deutschland GmbH Humanes und murines Semaphorin L
CN102089430B (zh) * 2008-05-09 2015-02-04 Abbvie公司 针对渐进性糖化终极产物受体(rage)的抗体及其用途
EA029023B1 (ru) * 2011-10-11 2018-01-31 Вэксинекс, Инк. Применение молекул, связывающих семафорин-4d, для модуляции проницаемости гематоэнцефалического барьера
US10494440B2 (en) * 2012-05-11 2019-12-03 Vaccinex, Inc. Use of semaphorin-4D binding molecules to promote neurogenesis following stroke
NZ630881A (en) * 2013-10-10 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treatment of atherosclerosis
NZ630892A (en) * 2013-10-21 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treating neurodegenerative disorders
WO2017011746A1 (en) * 2015-07-15 2017-01-19 Adm Diagnostics, Llc System and methods for determining a brain condition of a patient sybject to multiple disease states

Similar Documents

Publication Publication Date Title
RU2019122337A (ru) Раннее обнаружение активации глиальных клеток при нейродегенеративных или нейровоспалительных заболеваниях
Pavese et al. Progression of monoaminergic dysfunction in Parkinson's disease: a longitudinal 18F-dopa PET study
JP2020536097A5 (cg-RX-API-DMAC7.html)
JP2022145965A (ja) アルツハイマー病を治療する方法
RU2009140134A (ru) Способы и композиции для лечения и мониторинга лечения связанных с ил-13 нарушений
TW201607956A (zh) 人類化抗-tau抗體
CA2967897A1 (en) Methods for treating alzheimer's disease
RU2015145610A (ru) Применение биомаркеров для оценки лечения желудочно-кишечных воспалительных расстройств антагонистами бета7 интегрина
JP2018526330A5 (cg-RX-API-DMAC7.html)
WO2023283650A1 (en) Biomarkers for alzheimer's disease treatment
EP4626918A1 (en) Methods of treatment using a tau pet level
CN120583962A (zh) 抗N3pGluβ淀粉样蛋白抗体、其剂量及其用途
US20230287114A1 (en) Use of an anti-cd19 antibody to treat autoimmune disease
JP2024540294A (ja) アルツハイマー病を治療するための方法
KR20240115910A (ko) 항-아밀로이드 베타 원섬유 항체 및 항-타우 항체의 사용 방법
AU2021324842A1 (en) Methods for treating multiple sclerosis with ocrelizumab
NZ755446B2 (en) Early detection of glial cell activation in neurodegenerative or neuroinflammatory diseases
CA3211305A1 (en) Anti-n3pglu amyloid beta antibodies and uses thereof
JP2019532034A (ja) 投与レジメン
WO2026025002A1 (en) Methods of treating neurological disorders with anti-abeta antibodies
WO2025064824A1 (en) Methods for treating alzheimer's disease
WO2026062585A1 (en) Methods of treatment using anti-trem2 antibodies
WO2025240435A1 (en) Methods of treating neurological disorders with anti-abeta antibodies
WO2025147562A9 (en) Methods of treating neurological disorders with anti-abeta antibodies
WO2026062582A1 (en) Methods of treatment using anti-trem2 antibodies